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1. Introduction  
Chronic alcohol abuse is a major precipitating cause of pancreatitis along with genetic 
predisposition. Chronic alcohol and alcohol metabolite exposure can produce profound 
pancreatic tissue destruction in addition to damaging effects to other organs (Apte et al., 
2009; Pezzilli et al., 2009). Pancreatitis causes over 2,000 deaths per year and over 100,000 
hospitalizations. Acute initial attacks can be fatal and about 20% of these elevate to chronic 
conditions which are irreversible. Chronic pancreatitis places patients at 50-60% increased 
risk of progressing to pancreatic cancer. Severe unmitigated pain is synonymous with 
pancreatic inflammation and cancer caused by fibrotic blockage of the ductal system, 
premature trypsin activation, inflammation, perineural damage and nerve exposure. 
Pancreatitis is characterized by severe histopathological changes, such as the presence of 
inflammatory mediators, acinar atrophy, fat necrosis, intraductal hemorrhage, periductal 
fibrosis and stromal proliferation (Schmidt et al., 1995). Elevated serum -amylase, lipase, 
and CRP levels serve as biochemical markers of acute pancreatitis (Merkord et al., 1997; 
Sparmann et al., 1997). Acute pancreatitis ranges from mild edematous conditions that 
usually heal without intervention, to severe hemorrhagic necrotizing inflammation that is 
often fatal over a period of days as patients succumb to abdominal sepsis and multi-organ 
failure (Schmidt et al., 1992; Vardanyan and Rilo, 2010). The level of pain experienced by 
these patients is directly linked to decreased pancreatic functioning and increased length of 
stay during hospitalizations. In patient surveys, 32% of patients in chronic pancreatitis pain 
report being willing to try any new therapy for relief, and some may resort to suicide for this 
intractable pain state. Thus, the need to pursue novel pain relief strategies remains high for 
patients with chronic pancreatitis pain and those with pancreatic cancer who now have 
increasingly longer survival times.  
2. Acute and chronic pancreatitis models: histological features  
We have examined several in vivo and in vitro models of alcohol injury in combination with 
a gene therapy approach to examine ability to reduce the consequences of alcohol related 
injury. An acute inflammatory pancreatitis is induced in rats with a noxious chemical, 
dibutyltin dichloride, used in fertilizers and plastics manufacturing. A chronic pancreatitis is 
induced by maintenance on a high fat and alcohol (6%) diet. Both the chemical and the diet 
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induced pancreatitis models produce histologically evident damage to the chymotrypsin 
producing acinar cells, inflammatory cell invasion and activation, interstitial edema, cell 
swelling and proliferation of local tissue stellate immune cells within the pancreas (Fig. 1; 
Lu et al., 2007; Yang et al., 2008).  
 
Fig. 1. Histopathology of rat pancreas at week 10. A. Naïve animals were fed low soy chow 
and given no treatment. B. Method control animals given the alcohol (6%) and high-fat diet 
to induce pancreatitis were given pancreatic injection of vehicle (DMEM) only. C. Some 
animals with alcohol and high-fat diet induced pancreatitis were given pancreatic HSV-β-
gal applications, serving as the vector control. Note the steatosis, inflammatory cell 
infiltration (arrows), acinar cell necrosis, tissue edema, ductal widening and periductal 
fibrosis seen in the controls, with alcohol and high-fat diet induced pancreatitis given 
vehicle or the HSV-β-gal applications (B and C). D. Greatly reduced inflammatory cell 
infiltration and preservation of pancreatic tissue architecture was seen in animals fed the 
alcohol and high-fat diet but treated with the HSV-ENK vector. The histopathology of the 
HSV-ENK vector treated animals was similar to that of the naïve animals (A). Hemotoxylin 
and eosin (H&E) stain. (Reprinted from Yang et al., 2008) 
3. Acute and chronic pancreatitis models: pain related behaviors 
These pancreatitis models also produce pain related behaviors. The novel open field test box 
revealed significant reductions in active behavioral measures (exploratory rearing; beam 
breaks; active time, duration, distance traveled), as well as increased rest time for animals 
with acute pancreatitis (Fig. 2). 
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Fig. 2. Hot plate response latency nociceptive behavior measurements. Hot plate response 
latency measurements are shown for naïve animals and animal groups with alcohol and 
high-fat induced pancreatitis. Hot plate test was conducted at baseline before induction of 
pancreatitis and for ten weeks subsequently. Note the significant shortening of hot plate 
response latencies for rats on the high fat and alcohol diet after week 3, indicating 
sensitization. The HSV-ENK treatment (arrow) significantly abrogated the shift in response 
latency for at least four weeks. Four weeks is typical of HSV vector expression. (Reprinted 
from Yang et al., 2008) 
4. Opiate gene therapy studies 
In initial fMRI studies using the acute DBTC induced pancreatitis model, we determined 
levels of neuronal activation in higher brain centers along the visceral pain pathway 
(Westlund, 2000) finding significant activation in rostral ventrolateral medulla, dorsal raphe, 
periaqueductal grey, medial thalamus and central amygdala in rats (Westlund et al., 2009). 
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The pancreatitis induced brain activation was reduced by administration of morphine. Thus, 
we subsequently studied reduction of histological and behavioral consequences of the 
Herpes viral vectors (HSV-1) that overexpress the precursor of the endogenous opiate met-
enkephalin in both the acute and chronic pancreatitis models. The gene therapy approach 
was used to overexpress the precursor for the endogenous opiate peptide met-enkephalin 
and was found to provide histological and behavioral mitigation of the histological (Fig. 1D) 
and behavioral changes (Fig. 2) induced by the pancreatitis. Met-enkephalin is an opioid 
growth factor known to increase wound healing and restore homeostasis in the cornea 
(Sassani et al., 2003).  
The chronic high fat diet and alcohol-induced pancreatitis allowed study of the full time 
course for enkephalin’s effectiveness (6 weeks) after a single inoculation directly into the 
pancreas (Yang et al., 2008; Westlund, 2009a). Met-enkephalin gene therapy is effective in 
the chronic alcohol diet induced pancreatitis model, as well as in an acute chemically 
induced model for reduction of tissue injury, fibrosis, inflammation, and pain-related 
behaviors (Lu et al., 2007; Yang et al., 2008; Westlund, 2009a). The fibrosis was abundant in 
animals with chronic pancreatitis and was stainable with picrosirius (overnight 0.1% Sirius 
red) as an addition to hemotoxylin/eosin histology (Fig. 3, right). Fibrosis produced by 
activated stellate cells characterizes the model as a chronic condition since it can lead to 
ductal stenosis that is one of the primary causes of pain for patients with pancreatitis. 
Histological data demonstrates that the proenkephalin gene product delivery to pancreas is 
reparative (Fig. 1D).  
   
Fig. 3. Alcohol and high fat diet induced pancreatic fibrosis. Histological features evident 
in control pancreatic tissues (left) were severely disrupted in animals with chronic 
pancreatitis fed the high fat and alcohol diet (right). Fibrosis evident with Sirius red staining 
was abundant in the animals with pancreatitis and was less dense in animals given the HSV-
1 proenkephalin viral vector.  
Staining for met-enkephalin is elevated only in the group treated with the HSV-ENK 
overexpression vector in chronic alcohol diet fed rats after 10 weeks (Fig. 4, 5), as well as in 
the chemically induced pancreatitis at one week. Immunohistochemical localization of the 
HSV-1 proenkephalin overexpression product, met-enkephalin, was identified in abundance 
in both the spinal cord (Fig. 4D) and the pancreas (Fig. 5D). Levels of met-enkephalin in 
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Fig. 4. met-Enkephalin immunohistochemical staining in spinal cord (T9–10). A. The 
spinal cord from a naïve rat is shown for comparison to (B) the spinal cord of animals with 
diet-induced pancreatitis at week 10. C. The expression of met-ENK after application of 
vehicle or HSV-β-gal is similar to naïve rats (A). D. Met-ENK expression was significantly 
increased in HSV-ENK vector-treated animals compared to controls. Met-ENK in the dorsal 
horn (laminae I–II) of the thoracic spinal cord was increased bilaterally. (Reprinted from 
Yang et al., 2008) 
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Fig. 5. met-Enkephalin immunohistochemical staining in pancreas. Photomicrographs and 
quantification of immunohistochemical staining for met-enkephalin in pancreas are shown 
for week 10. Minimal or no staining is seen in pancreas of (A) naïve and (B-C) control 
animals with alcohol and high-fat diet induced pancreatitis. D. Met-ENK expression was 
significantly increased in the pancreas of HSV-ENK-treated animals fed the same diet 
compared to the controls. (Reprinted from Yang et al., 2008) 
www.intechopen.com
 Gene Therapy Approach: HSV-Enkephalin Reduces Fibrosis, Inflammation, and Pain 
 
19 
pancreas were measured in a small number of animals with HPLC after one week of acute 
DBTC-induced pancreatitis. Levels, barely detectable in control pancreas, increase to about 
3500ng/ml after one week of met-enkephalin overexpression. No staining for met-
enkephalin was evident in naïve, vehicle or in animals receiving control viral vector (Fig. 
4A-C, 5A-C).  
There is negligible RANTES staining in naïve controls (Fig 6A) or animals with pancreatitis 
after met-enkephalin overexpression (Fig 6D) with either model indicating met-enkephalin 
protects the pancreas from effects of invading inflammatory cells. Staining for the 
inflammatory mediator RANTES is clearly evident in the pancreas in vehicle- and HSV-β-
gal-treated animals with pancreatitis at week 10 (Fig 6B and 6C, respectively) at week 10. 
Both acinar cells and infiltrating inflammatory cells were positive for RANTES and COX-2 
at one week (not shown). 
 
Fig. 6. RANTES immunohistochemical staining in pancreas. Photomicrographs of 
immunohistochemical staining of RANTES in the pancreas of rats are shown for week 10. A. 
Naïve rat pancreas. B. Diet-induced pancreatitis and application of vehicle as control. C. 
Diet-induced pancreatitis and application of the HSV-β-gal control vector. D. Animals given 
the same diet and application of HSV-ENK. Note the increased RANTES staining in 
pancreata of animals with alcohol and high-fat diet induced pancreatitis treated with vehicle 
or HSV-β-gal applications. Little or no staining of RANTES is noted in naïve and HSV-ENK-
treated animals. (Reprinted from Yang et al., 2008) 
We propose that met-enkephalin is acting as a protective/restorative agent against pancreatic 
insult. Met-enkephalin acts on -opioid receptors that we observed in pancreatic acinar and 
stellate cells in our chemically induced pancreatitis model (Lu et al., 2007). Increased 
expression of -opioid receptors was detected in the pancreas with the DBTC induced acute 
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pancreatitis at one week. The -opioid receptors induced in pancreas by DBTC pancreatitis 
are reduced by HSV-enkephalin except in stellate cells  (Lu et al., 2007). 
In our studies, HSV-ENK injected rats with pancreatitis have normal or nearly normal 
responses to noxious heat (Fig. 2). Opioid peptides generated from three precursor genes, 
proenkephalin, prodynorphin and POMC, are conserved phylogenetically (Salzet, 2001). 
The mechanism of action for reduction of pain related behaviors in this and previous studies 
are likely related to enkephalin’s influence directly both on the central and the peripheral 
opioid receptors by the overexpressed met-enkephalin at those sites (Figures 4, 5). 
Proenkephalin derived opioid peptides are released peripherally after HSV-ENK 
administration (Yeomans et al., 2006). Their effect would mimic the enhanced endogenous 
release of opiates from immune cells that invade the region of inflammation and modulate 
both pain and inflammatory parameters (Stein, 1995). While many of the opiate peptides are 
delivered by inflammatory cells drawn to sites of inflammation, opioid neuropeptides may 
be more prominent in influencing nociceptive signaling when delivered at the synaptic 
endings. Proenkephalin gene product met-enkephalin is expressed in a 3:1 ratio relative to 
proenkephalin gene product, leu-enkephalin. The factors regulating why some gene 
products from the opioid families have more efficient translational processing, or are 
expressed in greater ratios is not completely understood (Danielson and Dores, 1999). The 
proenkephalin viral construct is chosen for proposed gene therapy pain studies since it is 
more prominent in influencing nociception.  
The opioid-mediated anti-hyperalgesia of HSV-ENK infected animals mimics the effects of 
endogenous or intrathecally administered enkephalin in our hands. However, enkephalins 
are very labile and the natural neuronal ending release provided by the HSV-1 viral vector is 
a superior release method. In a cutaneous inflammation model, HSV-ENK infected animals 
were no different from controls suggesting that opioids are not tonically released, but are 
released only when there is a substantial activation of the afferents providing evidence that 
hyperalgesia can be blocked without altering baseline nociception (Wilson et al., 1999).  
Our studies were equally successful with replication conditional or replication defective 
viral constructs. Both effectively reduce nociceptive behaviors in our models and in somatic 
pain models in previous studies (Wilson et al., 1999) but have no effect in control animals. 
Previous studies of HSV-1 transgene therapy have been used successfully to assess the anti-
nociceptive effects of transduced opioids in inflammatory models, including experimental 
models of cutaneous inflammation and polyarthritis (Braz et al., 2001; Wilson et al., 1999; 
Wilson and Yeomans, 2000; Wilson and Yeomans, 2002). In the previous studies, application 
of HSV-1 virus vector containing a human proenkephalin gene resulted in transmission by 
viral spread through primary afferent fibers into the dorsal root ganglia. Subsequent protein 
expression from the proenkephalin or ß-galactosidase gene (control neutral protein) could 
be visualized in the spinal cord (Wilson et al., 1999). Human proenkephalin-encoding HSV-1 
viral vector reduced hyperalgesia by 60% in a polyarthritis model (Braz et al., 2001). 
Histological and behavioral effects were observed at 4-9 days post-infection (Wilson et al, 
1999). The maximal response after hindpaw application of HSV-1 enkephalin-coding viral 
vector was reported at 14 days (Braz et al., 2001). Both of these studies validate that time is 
required for incorporation of viral vectors into nerve terminals, for retrograde transport of 
the viral vector to the DRG, and for subsequent peptide production.  
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Additional findings in the experimental polyarthritis model reported by Braz and colleagues 
(2001) was clear radiographic evidence that the animals receiving the HSV enkephalin gene 
encoding viral vectors also sustained significantly less joint destruction than the control 
animals after CFA injection. Both studies demonstrated that the opioid receptor antagonist, 
naloxone, delivered subcutaneously or intrathecally, could partially or completely restore 
sensitization in the HSV-1 enkephalin encoding vector infected animals but had no effect on 
HSV-1-ß-galactosidase encoding vector or mock infected animals. This suggests opioid 
mediation of observed anti-nociceptive effects and suggests that the effect was in part due to 
spinal release of opioids. Naloxone methiodide administration increased hyperalgesia in 
animals infected with HSV-ENK when administered for three days (Braz et al., 2001). In 
another model, HSV-ENK delivery by intradermal application was as effective in controlling 
pain related measures as intrathecal administration of enkephalin (Wilson et al., 1999). 
These and our studies are compelling in that HSV-1 opioid gene delivery potentially offers a 
significantly sustained response (up to 7 weeks) in the experimental rodent models. Thus, 
analgesia and restorative effects of HSV-Enk gene therapy will likely be effective in both 
somatic and visceral clinical pain.  
5. Viral vectors: analgesic and anti-inflammatory potential  
Few studies to date report effective decreases in ongoing visceral pain with pharmacological 
treatments other than with opiates. Activation of opiate receptors leads to potent analgesia 
(Schafer et al., 1998), and opiates remain the primary therapeutic agent despite significant 
side effects and development of tolerance. Gene therapy is a novel drug delivery system 
capable of bringing over-expressed opiates directly to pancreatic tissues. The site specific 
delivery of HSV-1 viral vectors, which have an affinity for uptake by primary sensory 
neuronal endings (neurotropic), provided the preferable gene delivery construct for visceral 
anti-nociception. Wild type HSV-1 is a 154 Kb neurotropic double stranded DNA virus, 
containing 84 essential and nonessential viral genes. After natural primary cutaneous or 
mucosal inoculation, viral particles enter sensory axon terminals innervating the affected 
area. They are carried by retrograde axonal transport from the periphery to DRG, where the 
virus may establish a life-long latent state (Burton et al., 2001; Steiner et al., 1990). For gene 
therapy applications, the modified HSV-1 nucleocapsid and tegument can also use the same 
transport mechanism for successful passage to DRG. Modified viruses have been 
constructed and used successfully in many pre-clinical studies and Phase I/II clinical 
trials. Results of trials are published at www.oxtl.com. In one strategy, replication 
defective viral constructs have deletions of essential immediate early genes from the HSV-
1 genome. In another strategy, replication conditional viruses are generated by insertion 
of the desired gene into the HSV-1 genes required for productive infections (i.e. thymidine 
kinase gene).  
A recent Phase I clinical trial administered a replication defective HSV vector similar to the 
one given in our studies to upregulate proenkephalin (Wolfe et al., 2009b). The clinical 
report indicates that the vector provided significant pain relief for 12–24 patients with 
intractable focal pain from terminal cancer. 
There are several inherent advantages to using HSV based viral constructs for foreign gene 
delivery in certain clinical settings, rather than other viral delivery models under study. The 
inserted genes are under the control of a strong constitutive human cytomegalovirus 
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promoter (hCMV), which allows expression of inserted gene product at an intracellular 
locale, in the absence of productive HSV-1 infection and without integration into the host 
genome (Wilson et al., 1999). The recombinant viral vectors designed for gene therapy 
rendered replication conditional or defective do not produce productive viral infection in 
vivo, but can persist for months despite negligible viral protein synthesis. These viral 
constructs establish a quiescent state similar to natural viral latency but cannot reactivate to 
cause active infection in neuronal cells in vivo (Goins et al., 2001; Wilson et al., 1999; Wilson 
and Yeomans, 2002). Lentiviruses as vectors offer very efficient infection, gene expression in 
activated cells and genome integration into host DNA for gene replacement therapy. 
However, current lentiviral constructs result in systemic infection and cannot be contained 
and the site of lentiviral insertion into the host genome cannot be controlled.They are 
considered a potential causal agent of cancers, autoimmune diseases and acquired immune 
deficiency syndrome (AIDS). Potential concerns exist regarding development of helper 
phenonoma for unwanted expressions and genetic recombination with other lentiviruses, 
including those already integrated in the host genome. Viral construct design for 
adenoviruses has also yielded promising results, but adenoviruses may not be 
advantageous since they can also involve the central nervous system.  
HSV-1 viral constructs may offer unique advantages in peripheral inflammation, as they 
selectively infect primary sensory neurons but do not integrate into the host genome. Thus, 
they will be an independent “minipump” source for protein synthesis in the neuronal 
cytoplasm. As a DNA-based viral construct, (1) the rate of mutation and recombination in 
these HSV-1 constructs will be minimal to nonexistent since (2) these constructs do not enter 
into productive infection or latency phases. Further, preliminary data suggest that HSV 
replication deficient viral constructs do not generate proteins that would induce an amnestic 
response from the host, activating latent prior HSV-1 infection. These are very important 
properties of HSV-1 based viral vectors, as 70-90% of the human adult population has 
evidence of prior HSV-1 infection. This limited potential to generate a host response also 
improves the potential for using repeated dosings of HSV-based viral constructs. 
Adenoviruses cause productive infection, induce host inflammation above the inflammation 
already generated in target tissues and increase potential for extended injury and host 
innate immune response to the virus making repeated doses problematic (Minter et al., 
2001). 
Local injection of HSV-1 viral construct with human proenkephalin gene insert results in 
targeted tissue expression of opioid protein (Yeomans et al., 2006), whereas systemic 
administration of some neural agents have undesirable or intolerable side effects (Goss et al., 
2002). HSV-1 gene delivery and local opioid expression may potentiate exogenously 
administered morphine, lowering doses needed and delaying morphine tolerance (Stein et 
al., 1996). This has been demonstrated in other HSV-based gene therapy models, where 
HSV-viral vector infections potentiated chemotherapy agents in lung cancer (Toyoizumi et 
al., 1999) and breast cancer (Thomas and Fraser, 2003). Attenuated herpes simplex viruses 
have already been successfully used in Phase I/II trials for treatment of CNS glioblastoma 
without apparent nonspecific toxic effects (Papanastassiou et al., 2002). The efficacy and 
potency of peripheral opioid effects are generally enhanced when drugs are administered 
during active inflammatory conditions (Antonijevic et al., 1995; Lamigeon et al., 2001; 
Schafer et al., 1998; Stein, 1995; Walker, 2003). 
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6. Anti-inflammatory effects and tissue protection by HSV-Enk treatment 
It is well known that long term administration of morphine reduces immune function 
through reduced hypothalamic-pituitary-adrenal axis activation. Opioid receptors are 
constitutively expressed in non-neuronal sites including vascular endothelial cells (Cadet et 
al., 2000 and Saeed et al., 2000), on immune cells such as macrophages and lymphocytes 
(Gavériaux et al., 1995), and keratinocytes (Bigliardi et al., 2002). A role for neuronal opiates 
has also been shown for reduction of inflammation (for review see Machelska and Stein, 
2003). While the role/s of specific extra-neuronal peripheral opioid receptors has not been 
fully established, mu (morphine), kappa (U50488H) and delta-2 (deltorphin II), but not 
delta-1 (DPDPE) opioid agonists have been shown to produce dose-dependent 
immunosuppressive effects on a plaque-forming assay, effects that were blocked by 
respective selective opioid antagonists (Rahim et al., 2001). It is also well established that the 
spinal cord can regulate peripheral inflammation through a variety of dorsal horn receptor 
mechanisms and retrograde primary afferent activity (Rees et al., 1994; Ren and Dubner, 
1999; Sluka et al., 1993; Sluka et al., 1994; Sluka and Westlund, 1993; Sorkin et al., 2003). This 
includes glutamate, GABA, substance P and adenosine receptor mechanisms likely 
influenced by opiates (Boyle et al., 2002). Much less well studied is the report that mu 
opiates can directly reduce plasma extravasation ((24-36%) Joris et al., 1990; Binder et al., 
2001; Green and Levine, 1992; Barber et al., 1993; Taylor et al., 2000). These effects are 
induced by activation of opioid receptors located in the central and peripheral nervous 
systems. In the periphery, opioid receptors are expressed on a significant proportion of 
capsaicin sensitive sensory fibers and sympathetic postganglionic terminals, where they 
may participate in the modulation of nociceptive information under certain pathological 
conditions (Zhou et al., 1998). The reversibility of the effects induced by the opioid receptor 
agonists (edema and extravasation) has been established after the administration of 
antagonists (i.p.) (Romero et al., 2005). The work of Lei and Rogers (1999) in intact 
respiratory tissue suggests that opioid receptors located on sensory fibers and immune cells 
are selectively activated by low (neuronal) or high (non-neuronal) doses of mu- and delta-
opioid receptor agonists. The local administration of mu- and delta-opioid receptor agonists, 
at doses that show no systemic effect, has been shown to decrease plasma extravasation 
during peripheral inflammation (Hong and Abbott, 1995). This suggests a clinical 
application for low dose morphine or met-enk as a pre-emptive treatment to avoid 
endoscopic procedure induced pancreatitis. It is likely that a similar mechanism is reducing 
inflammatory signs in the HSV-ENK treated animals releasing enkephalin directly to the 
pancreas.  
7. Development of opiate tolerance? 
In our study, hyperalgesia in the control HSV--gal and vehicle treated animals with alcohol 
and high fat diet induced pancreatitis was maintained through seven weeks. The 
overexpression of the proenkephalin products in the HSV-ENK treated animals was 
sufficient to abrogate the effects of the pancreatitis for an extended period of time without 
tolerance demonstrating that this is an adequate model for treatment in clinical studies. The 
important issue of desensitization and tolerance to the enkephalin generated by the HSV-
ENK construct, appears to be a non-issue in the time frame of study. We propose that it is 
the release of met-enkephalin directly onto receptors at nerve terminals both centrally and 
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peripherally that provides additive effectiveness for reducing hyperalgesia and tissue 
protection from inflammatory responses without tolerance. In this site directed manner, 
enkephalin can affect receptors on neuronal endings that receive information about noxious 
conditions in the pancreas and have reparative ability as an apparent added benefit. 
Standard therapies relying on higher and higher levels of circulating opiates, on the other 
hand, frequently result in intolerable side-effects and development of tolerance. Gene 
therapy using HSV vectors for gene product delivery may be clinically preferred in patients 
with prospects of longer life spans and functionality, or in intractable chronic nonmalignant 
pancreatitis and generally indicated in patients with longer life spans. HSV-1-based viral 
vector infections may offer a novel, effective, well-tolerated and advantageous approach 
for treatment of chronic pancreatic pain in patients. This approach might also be 
expanded to deliver additional human gene products that could impact the pain, 
inflammation, structural integrity and repair of the pancreas in patients.  
8. Testing safety and efficacy issues 
Safety and efficacy of replication defective HSV vectors have already been demonstrated for 
other purposes in Phase 1 clinical trials (Todo, 2002; Shah 2003; Yu et al, 2004; Satoh, 2005; 
Sawai et al., 2001; Wolfe et al., 2009, a,b). For our studies we examined the spinal cord for 
evidence of HSV-1 infection after 12 weeks of study. While we expected and have 
demonstrated HSV-1 in the dorsal root ganglia sensory neurons (Yang et al., 2008), the 
preferred host cell for HSV, no central nervous system infection was found. This has not been 
tested in spinal cord previously with these viral vectors. The replication deficient virus has 
already been used safely when injected directly into the brain as a treatment for glioblastoma 
(Papanastassiou, et al., 2002). The efficacy and clinical relevance of the direct injection into the 
pancreas was successfully tested in our pre-clinical studies by examining behavioral, 
inflammatory and cellular activation responses, such as FOS protein expression in spinal 
neurons and phospho-p38 in DRG. Effects of met-enkephalin have also been tested in in vitro 
pancreatic cell models. We have infected DRG and pancreas cells in cultures (PANC-1) with 
HSV vectors to assess the longevity of enkephalin, inflammatory mediator release, re-
activation and other safety issues in PANC-1 cells, clonal human pancreatic tumor-derived 
tubular epithelia equivalent to the cells lining the pancreatic ducts. The PANC-1 cells have 
been used previously by Eisenberg et al. (2005) to assess increased efficacy of HSV vectors 
used as an anti-cancer adjuvant to chemotherapeutic agents. In our studies the proenkephalin 
overexpression significantly reduced cytokine expression (unpublished data). 
The phase I clinical trial using a related replication defective viral vector reported successful 
reduction of pain levels assessed using a numeric rating scale (NRS), the Short Form McGill 
Pain Questionnaire (SF-MPQ) and concurrent reduction of opiate usage in the terminal 
cancer patients initially with intractable pain (Wolfe et al., 2009b). The gene therapy studies 
provide compelling new insights in support of the effectiveness of enkephalin for reduction 
of tissue injury, fibrosis, inflammation, and pain related behaviors. The HSV viral system 
offers great potential for simultaneous delivery of multiple other gene products, as the HSV 
vector cassette is very large. Further improvement of vector system design may provide 
other anti-inflammatory gene products to protect and restore functional integrity of 
damaged tissues.  
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9. Clinical significance  
As pancreatitis patient survival is becoming a fortunate reality, consideration of route of 
administration for viral constructs should be a part of investigative pre-clinical studies. 
While celiac plexus neurolysis is a currently accepted clinical treatment for severe 
intractable abdominal pain in abdominal malignancies and chronic pancreatitis, it is usually 
reserved for patients who have failed other treatment modalities. The reported year 1 
success rate for pain relief is reportedly between 57-100%, depending on the approach and 
ethanol concentration (Okuyama et al., 2002; Vranken et al, 2002; Schmulewitz and Hawes, 
2003; Klapman and Chang, 2005). Celiac plexus neurolysis requires surgical or anesthetic 
specialization and is usually performed at tertiary referral centers. Some procedural 
approaches require an epidural block for anesthesia. Although generally well-tolerated, 
reported complications include back pain, hypotension, and diarrhea (Chan, 1996; Kulke, 
2002). Celiac plexus neurolysis essentially scleroses the nerve and blocks the afferent and 
efferent transmission of all neurochemicals. Neural blockade of a significant part of the 
enteric sympathetic nervous system in an otherwise functioning enteric system may lead to 
pancreatic or enteric pathologies, as the sympathetic nervous system plays a vital role in 
modulating intestinal secretory and absorptive processes. This may become more of an issue 
with the improved cancer treatments and longer lifespan for pancreatic malignancies. Viral 
vectors could be administered to coeliac ganglia in patients by anesthesiologists. However, 
it is not entirely clear that HSV-Enk would have sufficient uptake efficiency from the axons 
themselves as the primary afferents pass through the sympathetic ganglia and do not 
terminate there. We will compare sympathetic ganglia injections to administration at the 
pancreatic terminal endings which already appears to be quite robust. Our studies imply 
that chronic infusions of HSV vectors directly onto the pancreas surface from implantable, 
transcutaneously refillable pumps would provide relief from chronic pain. This potential 
treatment would also be nerve plexus sparing and avoid the severe complications of 
pancreatic duct disruption encountered by endoscopists. The sparing of neural connections 
would decrease the potential for pancreatic insufficiency and enteric damage.  
Pancreatic cancer and chronic pancreatitis are among those syndromes characterized as 
causing the most severe pain states. Pancreatic cancer is the 4th leading cause of cancer 
deaths in the US, and over 70% of pancreatic cancer patients have significant debilitating 
abdominal pain upon clinical presentation. Over 50% of patients with idiopathic and 
alcoholic pancreatitis report chronic pain. The current treatment of pain in pancreatic cancer 
and chronic pancreatitis includes parenteral narcotic agents, surgical intervention at the 
level of pancreas or neural pathways and complementary therapies. Narcotic agents are not 
optimal as there are risks of tolerance, addiction and intolerable side effects of sedation and 
constipation and nausea. Surgical intervention with total pancreatectomy and islet 
autotransplantation provides pain relief for a considerable number of patients (Blondet et 
al., 2007; Hildebrand et al., 2011). However, surgery is invasive and can result in transient or 
suboptimal relief of pain, postoperative diabetes, and maldigestion. Surgery may be 
therapeutically or fiscally inappropriate based on the clinical status of some patients. 
Chronic abdominal pain from the pancreas has a significant negative long term impact on 
patient quality of life and mortality as it profoundly decreases appetite and leads to weight 
loss. When patients lose >20% of lean body mass, host immunocompetence is profoundly 
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impaired. Therefore, effective management of pain is imperative, not just for the 
legitimate concern for pain’s sake, but for improvement in physical functioning, general 
health, patient survival, quality of life, and functional independence. Effective 
management of chronic pain would lift the economic burden of pain-induced debilitation 
on the individual, their support system and public health.  
Pain is a serious public health problem, costing the US about 100 billion dollars/yr (JAHCO 
report). Pain is the single greatest cause of disability, decreased physical function, decreased 
work productivity, absenteeism, reactive depression and lower quality of life (QOL, i.e. 
SF36) scores. In fact, 40-60% of patients with chronic pain report it has significantly and 
negatively impacted their personal relationships, work productivity and daily routines of 
living. Considerable improvements have been made in opioid medications, in term of 
bioavailability, half-life, transdermal delivery, breakthrough opioid combinations and usage 
with enhancing drugs, such as tricyclic antidepressants. However, side effects and potential 
for opioid addiction remain a concern to the patient, health care providers and the 
community. About 60% of patients with chronic pain have expressed fears regarding 
narcotic medication side effects and fear of addiction to current narcotic regimens. In a 
Partners Against Pain Survey of 1000 patients in chronic pain, 50% of the patients reported 
difficulty >1 yr in getting their pain under control and 78% of the patients reported that they 
would be willing to try new treatments.  
Innovative Aspects of the Gene Therapy Studies 
Unique advantages offered by HSV-1 viral vector delivery of proenkephalin expression 
products by the peripheral nerves include: 
 Potential for simultaneous delivery of analgesic peptides to both peripheral and central 
sites, neuronal ending sites, optimizing the effects without tolerance 
 More effective and prolonged abrogation of nociceptive responses 
 Normalization of pain related behavior to near baseline levels as shown in the 
published studies 
 Potential for positive impact on pancreatic inflammation as shown in the published 
studies 
 HSV-1 viral constructs to be used are replication deficient/ defective  
 HSV-1 viral constructs will not incorporate into the host genome or become lytic 
 Focused delivery to the target organ allows a much lower viral titer (5-10X lower viral 
titer than in skin) 
 Potential for reduction/elimination of the use of narcotic drugs 
 Novel palliative strategy for alleviating the unremitting pain of pancreatic cancer and 
chronic pancreatitis 
10. Conclusion  
In summary, our studies indicate that the proenkephalin gene product delivery to pancreas 
is reparative and significantly reduce pain related behaviors in rodent pancreatitis models.  
Gene therapeutic approaches that promote the endogenous opiate enkephalin, particularly 
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delivery by the neuronal innervation, may have significant clinical relevance for reducing 
inflammation, pain-related behavior and tissue destruction.  
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